Our Pipeline

Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, urology and women’s health. Myriad’s research investment totals $358 million over the past five years.

The Science

At Myriad, we use state-of-the art technologies including DNA sequencing, RNA analysis and proteomics to innovate and create the next generation of breakthrough diagnostics.

Our talented scientists are working in collaboration with universities, biotech and pharmaceutical companies, and government agencies to accelerate the pace of innovation for patients worldwide. This approach affords us a diversity of perspectives as well as access to cutting-edge science regardless of where it resides.